What is the core business of Intuitive Surgical, Inc. as of the 2001 filing?

Intuitive Surgical designs, manufactures, and markets the da Vinci Surgical System, an advanced robotic system that enables surgeons to perform complex procedures with enhanced control, precision, and visualization through minimally invasive incisions. The company positions this as a 'third generation' of surgery.

What were the key financial performance indicators for Intuitive Surgical in 2001?

In 2001, Intuitive Surgical reported sales of $51.7 million, a 94% increase year-over-year. The company sold 49 da Vinci Surgical Systems. While gross profit margin improved to 45%, the company still incurred a net loss of $16.7 million, though this was a reduction from the previous year's loss.

What are the main risks and challenges highlighted by the company?

Key risks include the company's limited operating history, the unproven nature of the market for new surgical technologies, the possibility of future losses, long and variable sales cycles for the da Vinci system, reliance on a small number of customers, and the need for market acceptance by physicians and payors. The company is also involved in significant intellectual property litigation with competitors like Computer Motion and Brookhill-Wilk 1, LLC.

How is Intuitive Surgical addressing regulatory requirements and market access?

The company is subject to stringent FDA regulations for its medical devices, including obtaining 510(k) clearances or Premarket Approval (PMA). They have secured FDA clearance for the da Vinci system in various laparoscopic and thoracoscopic procedures and are pursuing further clearances for cardiac procedures. International regulatory approvals (like CE marking in Europe) are also crucial for global sales.

ISRG 10-K FY2001 Annual Report — Revenue, Net Income, EPS

Summary

Intuitive Surgical, Inc. (ISRG) reported its 2001 annual results, showcasing significant revenue growth driven by the increasing adoption of its revolutionary da Vinci Surgical System. The company's technology aims to redefine surgery by combining the precision of open surgery with the benefits of minimally invasive approaches. While sales have more than doubled year-over-year, the company continues to operate at a loss, a common characteristic for early-stage technology companies investing heavily in research, development, and market expansion. Despite the ongoing losses, the company's strong revenue trajectory and its position as a pioneer in robotic-assisted surgery are key indicators of its growth potential. Investors should note the substantial investments in R&D, sales, and marketing, which are critical for establishing market leadership and driving future adoption. The company's financial health is supported by its cash reserves, although future capital needs and potential equity dilution remain factors to monitor.

Key Highlights

1Revenue for the fiscal year ended December 31, 2001, reached $51.7 million, representing a 94% increase from $26.6 million in the prior year.
2The company sold 49 da Vinci Surgical Systems in 2001, a significant increase from 28 systems sold in 2000, indicating growing market adoption.
3Gross profit margin improved to 45% in 2001 from 32% in 2000, driven by increased sales and manufacturing efficiencies.
4Research and development expenses increased by 18% to $13.9 million in 2001, reflecting continued investment in product enhancement and new applications.
5Selling, general, and administrative expenses rose by 57% to $30.0 million in 2001, primarily due to headcount increases in sales and service to support growth.
6The company reported a net loss of $16.7 million for 2001, compared to a net loss of $18.5 million in 2000, showing progress in narrowing losses.
7As of December 31, 2001, Intuitive Surgical had $66.7 million in cash, cash equivalents, and short-term investments, providing a solid liquidity position.

INTUITIVE SURGICAL INC Annual Report, Year Ended Dec 31, 2001

Summary

Key Highlights

Frequently Asked Questions